局部晚期非小细胞肺癌诱导化疗后同期放化疗与同期放化疗疗效及安全性Meta分析
发布时间：2018-09-10 12:55
【摘要】：目的不可手术局部晚期非小细胞肺癌经诱导化疗后同期放化疗的获益情况尚缺乏证据。本研究通过对比不可切除局部晚期非小细胞肺癌经诱导化疗后同期放化疗与同期放化疗2种治疗模式下的疗效及安全性,望寻求对局部晚期非小细胞肺癌更有效的治疗方法,为临床治疗手段提供理论依据。方法计算机检索The Cochrane Library、PubMed、Embase、Web of Science、CBM和CNKI,同时辅佐其他检索途径,搜集2016-06前所有关于局部晚期非小细胞肺癌诱导化疗后同期放化疗与同期放化疗治模式的随机对照试验(randomized controlled clinical study,RCT)。质量评价参考2008年Cochrane质量评价标准,统计学分析应用Review Manager 5.2软件。结果共纳入11个RCT。诱导化疗后同期放化疗与同期放化疗治模式总有效率差异无统计学意义,OR=1.30,95%CI为0.96~1.77,P=0.10;1(OR=1.51,95%CI为0.97~2.43,P=0.07)和2(OR=1.34,95%CI:1.00~1.79,P=0.05)年生存率差异无统计学意义,3年生存率差异有统计学意义,OR=1.43,95%CI:1.02~2.01,P=0.04;Ⅲ~Ⅳ级不良反应中,放射性食管炎(OR=1.96,95%CI:1.06~3.62,P=0.03)和白细胞降低(OR=1.84,95%CI:1.24~2.74,P=0.002)差异有统计学意义,放射性肺炎(OR=1.31,95%CI:0.62~2.77,P=0.48)和恶心呕吐(OR=1.46,95%CI:0.82~2.59,P=0.19)差异无统计学意义。结论诱导化疗后同期放化疗组Ⅲ~Ⅳ级放射性食管炎、放射性肺炎及白细胞降低发生率较同期放化疗组增多,但无毒性相关死亡,而诱导化疗组3年生存率较同期放化疗组提高,可考虑为临床应用。
[Abstract]:Objective there is no evidence of the benefit of radiotherapy and chemotherapy after induction chemotherapy for non-operative advanced non-small cell lung cancer. In this study, the efficacy and safety of non-resectable local advanced non-small cell lung cancer (NSCLC) after induction chemotherapy and simultaneous radiotherapy and chemotherapy were compared, in order to find a more effective treatment for local advanced NSCLC. To provide theoretical basis for clinical treatment. Methods The Cochrane Library,PubMed,Embase,Web of Science,CBM and CNKI, were searched simultaneously with other search methods, and all the randomized controlled trials (randomized controlled clinical study,RCT) were collected before June 2016-06 about concurrent radiotherapy and chemotherapy after induction chemotherapy and concurrent radiotherapy and chemotherapy for local advanced non-small cell lung cancer (NSCLC). According to the quality evaluation standard of Cochrane in 2008, the software Review Manager 5.2 was used in statistical analysis. Results A total of 11 RCT. were included There was no significant difference in the total effective rate between the concurrent radiotherapy and chemotherapy after induction chemotherapy and the concurrent radiotherapy and chemotherapy. There was no significant difference in the total effective rate between the two models. The CI was 0.96 ~ 1.77% (OR=1.51,95%CI = 0.97 ~ 2.43) and 2 (OR=1.34,95%CI:1.00~1.79,P=0.05). There was no significant difference in the 3-year survival rate. There were significant differences in the 3-year survival rate between the OR1.439 95CI1.02P0.01P0.04 and the 鈪，
本文编号：2234503
[Abstract]:Objective there is no evidence of the benefit of radiotherapy and chemotherapy after induction chemotherapy for non-operative advanced non-small cell lung cancer. In this study, the efficacy and safety of non-resectable local advanced non-small cell lung cancer (NSCLC) after induction chemotherapy and simultaneous radiotherapy and chemotherapy were compared, in order to find a more effective treatment for local advanced NSCLC. To provide theoretical basis for clinical treatment. Methods The Cochrane Library,PubMed,Embase,Web of Science,CBM and CNKI, were searched simultaneously with other search methods, and all the randomized controlled trials (randomized controlled clinical study,RCT) were collected before June 2016-06 about concurrent radiotherapy and chemotherapy after induction chemotherapy and concurrent radiotherapy and chemotherapy for local advanced non-small cell lung cancer (NSCLC). According to the quality evaluation standard of Cochrane in 2008, the software Review Manager 5.2 was used in statistical analysis. Results A total of 11 RCT. were included There was no significant difference in the total effective rate between the concurrent radiotherapy and chemotherapy after induction chemotherapy and the concurrent radiotherapy and chemotherapy. There was no significant difference in the total effective rate between the two models. The CI was 0.96 ~ 1.77% (OR=1.51,95%CI = 0.97 ~ 2.43) and 2 (OR=1.34,95%CI:1.00~1.79,P=0.05). There was no significant difference in the 3-year survival rate. There were significant differences in the 3-year survival rate between the OR1.439 95CI1.02P0.01P0.04 and the 鈪，
本文编号：2234503
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2234503.html
